Human study confirms anxiety reducing effects of AnxioFit-1

Chiropractic EconomicsMay 10, 2012

May 10, 2012 — In a human clinical study published in the March issue of Phytotherapy Research, scientists found that AnxioFit-1 has a significant effect on relieving anxiety within only three days of use.

AnxioFit-1 is a highly specialized extract from a single form of echinacea (angustifolia), developed by the Hungarian Academy of Sciences. Past research has suggested that AnxioFit-1 attaches to cannabinoid receptors in the brain to elicit a sense of calm and relaxation, without drowsiness.

The study included 33 volunteers, 22 women, and 11 men with an average age of 41. All experienced mild anxiety. Anxiety was assessed using the State-Trait Anxiety Inventory (STAI), which is a clinically validated tool used to measure anxiety levels. Only individuals meeting the threshold for significant levels of anxiety were included in the study.

Subjects used AnxioFit-1 for one week, and anxiety was evaluated before, during, and after using the product. The daily dose (two 20 mg tablets per day) decreased STAI (both state and trait) scores within three days, an effect that remained stable for the duration of the treatment (seven days) and for the two weeks that followed treatment. There were no drop outs, demonstrating that the treatment was well tolerated. No serious adverse effects were recorded during the treatment period.

“Many people are surprised to find that there are unique compounds in echinacea that have a rapid effect on reducing anxiety and nervous tension,” states lead author Dr. Jozsef Haller. “AnxioFit-1 is a single spectrum of compounds found only in echinacea angustifolia. The extract is used at quite a low dose, which is 20 mg twice a day. This study confirms what we have seen in other AnxioFit-1 studies — that it is possible to greatly reduce anxiety without causing serious side effects and no issues with addiction or dependence.”